Who are Nabilone Capsules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cannabis Sativa Oil, Hemp, Cannabis Extract Oil SR Capsule, Cannabis oil, MediCabilis CBD Oil, Low-Dose Cannabidiol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nabilone-capsules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Nabilone Capsules — Competitive Intelligence Brief

Nabilone Capsules (Nabilone Capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Synthetic cannabinoid. Area: Oncology, Gastroenterology.

phase 3 Synthetic cannabinoid CB1 receptor, CB2 receptor Oncology, Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Nabilone Capsules (Nabilone Capsules) — Eldon Loh, MD. Nabilone is a synthetic cannabinoid that mimics THC and activates cannabinoid receptors in the central nervous system to reduce nausea and vomiting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Nabilone Capsules TARGET	Nabilone Capsules	Eldon Loh, MD	phase 3	Synthetic cannabinoid	CB1 receptor, CB2 receptor
Cannabis Sativa Oil	Cannabis Sativa Oil	Fondation pour l'accueil et l'hébérement des personnes âgées	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor
Hemp	Hemp	Thammasat University Hospital	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor, TRPV1, 5-HT1A receptor
Cannabis Extract Oil SR Capsule	Cannabis Extract Oil SR Capsule	University of Sao Paulo General Hospital	marketed	Cannabinoid receptor modulator	CB1 receptor, CB2 receptor
Cannabis oil	Cannabis oil	Assaf-Harofeh Medical Center	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor
MediCabilis CBD Oil	MediCabilis CBD Oil	Gold Coast Hospital and Health Service	marketed	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)
Low-Dose Cannabidiol	Low-Dose Cannabidiol	Wayne State University	phase 3	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Synthetic cannabinoid class)

Centre for Addiction and Mental Health · 1 drug in this class
Eldon Loh, MD · 1 drug in this class
NEMA Research, Inc. · 1 drug in this class
University of Calgary · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nabilone Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/nabilone-capsules. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab